This website does not function properly without javascript

Welcome to the Peeper lab website

Welcome to the Peeper laboratory website. We use function-based genetic approaches to aid the development of more durable clinical responses for cancer patients. We aim to identify specific tumor vulnerabilities for drug target and biomarker discovery and subsequently set up for clinical implementation. For example, we are screening for ways to enhance the activity, or avoid resistance, of currently used clinical compounds targeting tumor or immune cells.


daniel



To reach these goals, we develop and utilize in vitro and in vivo genome-wide functional perturbation screens for a better understanding of tumor heterogeneity and drug resistance as well as for the identification of factors amenable to pharmacologic intervention and predictive biomarkers. This is done for several cancer types including melanoma, lung and breast cancer. Given the advances made for immunotherapy, we have also begun establishing combinatorial systems allowing for including immunological factors in our genetic screens. Candidate genes are assessed and ranked computationally and subsequently functionally validated in clinically relevant models, including patient-derived xenografts.

Where possible, we team up with our clinical collaborators to implement our findings to the benefit of the patients.

News & highlights


  • vacancies(November 2015) Daniel Peeper receives Outstanding Research Award from the Society of Melanoma Research
  • vacanciesWe have job openings for a highly motivated postdoc (metabolomics) and for an ambitious molecular/medical biologist (immunology). For more info, click here
  • kemper2(June 2015) Kristels study on intra- and inter-tumor heterogeneity in patient-derived xenografts of melanoma has been published in EMBO Molecular Medicine
  • kuilman6(February 2015) Thomas' and Oscar's study on the use of off-target reads for copy number detection has been published in Genome Biology
  • vacanciesWe have job openings for a highly motivated postdoc (metabolomics) and for an ambitious molecular/medical biologist (immunology). For more info, click here
  • mueller(December 2014) Judith's study on the effect of the MITF/AXL ratio on targeted drug sensitivity in melanoma has been published in Nature Communications
  • smit3(November 2014) Patricia's study on synthetic lethality between hypoxia and DNA damage response inhibition has been published in Cell Reports
  • vacanciesWe have job openings for a highly motivated postdoc (metabolomics) and for an ambitious molecular/medical biologist (immunology). For more info, click here
  • smit3(November 2014) Marjon's study on combining Rock1 and RAS-signalling cascase inhibition in melanoma has been published in Molecular Systems Biology
  • kaplon(May 2013) Joanna's study on OIS, metabolism and melanoma therapy published in Nature with a preview in Cell and a research watch in Cancer Discovery.
  • vacanciesWe have job openings for a highly motivated postdoc (metabolomics) and for an ambitious molecular/medical biologist (immunology). For more info, click here
  • ERCsynergy(2013) Daniel Peeper, together with five other researchers, has received a 15M€ ERC Synergy grant.



logo